1. Home
  2. RCEL vs GRX Comparison

RCEL vs GRX Comparison

Compare RCEL & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCEL
  • GRX
  • Stock Information
  • Founded
  • RCEL N/A
  • GRX 2007
  • Country
  • RCEL United States
  • GRX United States
  • Employees
  • RCEL N/A
  • GRX N/A
  • Industry
  • RCEL Medical/Dental Instruments
  • GRX Finance/Investors Services
  • Sector
  • RCEL Health Care
  • GRX Finance
  • Exchange
  • RCEL Nasdaq
  • GRX Nasdaq
  • Market Cap
  • RCEL 161.5M
  • GRX 148.5M
  • IPO Year
  • RCEL N/A
  • GRX N/A
  • Fundamental
  • Price
  • RCEL $5.32
  • GRX $9.57
  • Analyst Decision
  • RCEL Strong Buy
  • GRX
  • Analyst Count
  • RCEL 4
  • GRX 0
  • Target Price
  • RCEL $16.50
  • GRX N/A
  • AVG Volume (30 Days)
  • RCEL 326.4K
  • GRX 39.7K
  • Earning Date
  • RCEL 08-07-2025
  • GRX 01-01-0001
  • Dividend Yield
  • RCEL N/A
  • GRX 5.98%
  • EPS Growth
  • RCEL N/A
  • GRX N/A
  • EPS
  • RCEL N/A
  • GRX 0.26
  • Revenue
  • RCEL $71,661,000.00
  • GRX N/A
  • Revenue This Year
  • RCEL $57.16
  • GRX N/A
  • Revenue Next Year
  • RCEL $36.69
  • GRX N/A
  • P/E Ratio
  • RCEL N/A
  • GRX $38.50
  • Revenue Growth
  • RCEL 41.35
  • GRX N/A
  • 52 Week Low
  • RCEL $4.71
  • GRX $7.73
  • 52 Week High
  • RCEL $14.16
  • GRX $10.40
  • Technical
  • Relative Strength Index (RSI)
  • RCEL 39.85
  • GRX 49.33
  • Support Level
  • RCEL $4.71
  • GRX $9.39
  • Resistance Level
  • RCEL $5.55
  • GRX $9.69
  • Average True Range (ATR)
  • RCEL 0.29
  • GRX 0.13
  • MACD
  • RCEL 0.08
  • GRX 0.00
  • Stochastic Oscillator
  • RCEL 41.03
  • GRX 44.46

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest

Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.

Share on Social Networks: